Ernexa Therapeutics Inc. (ERNA)
NASDAQ: ERNA · Real-Time Price · USD
0.2005
-0.0100 (-4.75%)
At close: Apr 2, 2026, 4:00 PM EDT
0.2000
-0.0005 (-0.25%)
After-hours: Apr 2, 2026, 7:16 PM EDT
Ernexa Therapeutics Employees
As of December 31, 2025, Ernexa Therapeutics had 7 total employees, including 5 full-time and 2 part-time employees. The number of employees increased by 1 or 16.67% compared to the previous year.
Employees
7
Change (1Y)
1
Growth (1Y)
16.67%
Revenue / Employee
n/a
Profits / Employee
-$2,014,286
Market Cap
5.85M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 7 | 1 | 16.67% | 5 | 2 |
| Dec 31, 2024 | 6 | -2 | -25.00% | 6 | 0 |
| Dec 31, 2023 | 8 | -1 | -11.11% | 8 | 0 |
| Dec 31, 2022 | 9 | -1 | -10.00% | 9 | 0 |
| Dec 31, 2021 | 10 | 0 | - | 10 | 0 |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Quince Therapeutics | 36 |
| Cardio Diagnostics Holdings | 17 |
| NuCana | 12 |
| Purple Biotech | 10 |
| XTL Biopharmaceuticals | 10 |
| MetaVia | 9 |
| Artelo Biosciences | 7 |
| Immuron | 7 |
ERNA News
- 2 days ago - Ernexa Therapeutics Highlights Key Catalysts as Company Advances Toward First-in-Human Clinical Trials in 2026 - GlobeNewsWire
- 5 weeks ago - Ernexa Therapeutics to Participate in Virtual Investor Closing Bell Series - GlobeNewsWire
- 7 weeks ago - Ernexa Therapeutics Announces Pricing of $10.5 Million Public Offering - GlobeNewsWire
- 2 months ago - Ernexa Therapeutics Participates in Virtual Investor “What This Means” Segment Highlighting Recent Successful Pre-IND Meeting with U.S. FDA - GlobeNewsWire
- 2 months ago - Ernexa Therapeutics Selected as One of Only Ten Global Companies for Prestigious JETRO Japan Entry Acceleration Program - GlobeNewsWire
- 3 months ago - Ernexa Therapeutics Announces Successful Pre-IND FDA Meeting and Continues Progress Toward First-in-Human Trial in Ovarian Cancer - GlobeNewsWire
- 4 months ago - Ernexa Therapeutics Presents New Preclinical Data at American Society of Hematology (ASH) Annual Meeting on Lead Cell Therapy Candidate for Treatment of Ovarian Cancer - GlobeNewsWire
- 4 months ago - Ernexa Therapeutics Announces Oral Presentation at the 67th American Society of Hematology (ASH) Annual Meeting - GlobeNewsWire